Correlation of Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Stroke Patients
Table 1
Clinical characteristics of the study population.
Variables
All patients (n = 890)
Non-DM (n = 610)
DM (n = 280)
value
Age (years)
66.7 ± 11.8
66.9 ± 12.0
66.4 ± 11.4
0.538
Female (n) (%)
329 (37.0%)
215 (35.2%)
114 (40.7%)
0.117
Current smoking (n) (%)
128 (14.4%)
100 (16.4%)
28 (10.0%)
0.012
Current drinking (n) (%)
75 (8.4%)
57 (9.3%)
18 (6.4%)
0.146
BMI (kg/m2)
20.7 ± 1.5
20.6 ± 1.5
20.8 ± 1.5
0.073
SBP (mmHg)
143.4 ± 21.4
142.3 ± 21.2
145.7 ± 21.8
0.032
DBP (mmHg)
83.9 ± 13.0
83.5 ± 13.0
84.7 ± 13.0
0.206
NIHSS score
1.0(0–3.0)
1.0(0–3.0)
1.0(0–2.0)
0.002
Modified Rankin Scale score
1.4 ± 0.8
1.4 ± 0.8
1.4 ± 0.8
0.929
Fasting plasma glucose (mmol/L)
6.4 ± 2.7
5.4 ± 1.1
8.5 ± 3.7
<0.001
Total cholesterol (mmol/L)
4.4 ± 1.1
4.4 ± 1.1
4.5 ± 1.3
0.418
Triglyceride (mmol/L)
1.4 ± 1.0
1.3 ± 0.8
1.7 ± 1.2
<0.001
LDL-c (mmol/L)
2.5 ± 0.9
2.5 ± 0.9
2.6 ± 1.1
0.073
HDL-c (mmol/L)
1.1 ± 0.3
1.2 ± 0.3
1.0 ± 0.3
<0.001
TRL-c (mmol/L)
0.7 ± 0.3
0.7 ± 0.3
0.8 ± 0.3
<0.001
Serum homocysteine (μmol/L)
13.2 ± 7.0
13.6 ± 7.2
12.3 ± 6.4
0.013
Hypertension (n) (%)
619 (69.6%)
390 (63.9%)
229 (81.8%)
<0.001
Dyslipidemia (n) (%)
425 (47.8%)
261 (42.8%)
164 (58.6%)
<0.001
Atrial fibrillation (n) (%)
106 (11.9%)
85 (13.9%)
21 (7.5%)
0.006
Antiplatelet drugs (n) (%)
790 (88.8%)
526 (86.2%)
264 (94.3%)
<0.001
Antihypertensive drugs (n) (%)
550 (61.8%)
356 (58.4%)
194 (69.3%)
0.002
Anticoagulant drugs (n) (%)
196 (22.0%)
345 (23.8%)
51 (18.2%)
0.063
Data are the mean ± SD, or number (percentage). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; NIHSS; modified Rankin Scale; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol, TRL-c: triglyceride-rich lipoprotein cholesterol.
